NGAL Correlates with Femoral and Carotid Plaque Volume Assessed by Sonographic 3D Plaque Volumetry.
atherosclerosis
biomarker
preventive medicine
ultrasound
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
31 Aug 2020
31 Aug 2020
Historique:
received:
13
08
2020
accepted:
27
08
2020
entrez:
4
9
2020
pubmed:
4
9
2020
medline:
4
9
2020
Statut:
epublish
Résumé
Inflammation represents a cornerstone in the development of atherosclerosis and early detection is essential to avoid cardiovascular events. Biomarkers like interleukin-1 beta, interleukin-6, or high sensitivity CRP (hs-CRP) have been investigated intensively in this field. Since they have several limitations, additional biomarkers are needed for cardiovascular risk stratification. The acute phase protein, neutrophil gelatinase-associated lipocalin (NGAL), modulates inflammation and is elevated in cardiovascular disease (CVD). Moreover, it contributes to plaque destabilization. In this prospective, single-center study, we included 323 asymptomatic patients with at least one cardiovascular risk factor or established CVD. NGAL levels were measured in plasma samples using a commercially available ELISA. Carotid, femoral, and total atherosclerotic plaque volumes (PV) were measured using a 3D ultrasound system (Philips iU22). Patients were separated into a low ( NGAL was significantly higher in patients with high total PV versus patients with low total PV. The NGAL amplitude for the prediction of high total PV was significantly higher when compared with hs-CRP. A high predictive value could also be observed for patients without established CVD. NGAL seems to be a promising biomarker for the identification of asymptomatic patients with atherosclerotic disease.
Sections du résumé
BACKGROUND/OBJECTIVES
OBJECTIVE
Inflammation represents a cornerstone in the development of atherosclerosis and early detection is essential to avoid cardiovascular events. Biomarkers like interleukin-1 beta, interleukin-6, or high sensitivity CRP (hs-CRP) have been investigated intensively in this field. Since they have several limitations, additional biomarkers are needed for cardiovascular risk stratification. The acute phase protein, neutrophil gelatinase-associated lipocalin (NGAL), modulates inflammation and is elevated in cardiovascular disease (CVD). Moreover, it contributes to plaque destabilization.
METHODS
METHODS
In this prospective, single-center study, we included 323 asymptomatic patients with at least one cardiovascular risk factor or established CVD. NGAL levels were measured in plasma samples using a commercially available ELISA. Carotid, femoral, and total atherosclerotic plaque volumes (PV) were measured using a 3D ultrasound system (Philips iU22). Patients were separated into a low (
RESULTS
RESULTS
NGAL was significantly higher in patients with high total PV versus patients with low total PV. The NGAL amplitude for the prediction of high total PV was significantly higher when compared with hs-CRP. A high predictive value could also be observed for patients without established CVD.
CONCLUSION
CONCLUSIONS
NGAL seems to be a promising biomarker for the identification of asymptomatic patients with atherosclerotic disease.
Identifiants
pubmed: 32878068
pii: jcm9092811
doi: 10.3390/jcm9092811
pmc: PMC7565934
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Cerebrovasc Dis. 2012;34(4):290-6
pubmed: 23128470
Clin Chem Lab Med. 2017 Nov 27;56(1):5-18
pubmed: 28672731
JAMA. 2008 Jul 9;300(2):197-208
pubmed: 18612117
Am Heart J. 2013 Dec;166(6):990-8
pubmed: 24268213
Clin Chem Lab Med. 2017 Nov 27;56(1):147-156
pubmed: 28672747
Kardiologiia. 2016 May;56(5):24-29
pubmed: 28294869
Blood. 1994 Feb 1;83(3):799-807
pubmed: 8298140
JACC Cardiovasc Imaging. 2012 Jul;5(7):681-9
pubmed: 22789936
Eur J Vasc Endovasc Surg. 2016 May;51(5):623-31
pubmed: 26947538
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
J Clin Med. 2018 Dec 31;8(1):
pubmed: 30602707
Caspian J Intern Med. 2013 Spring;4(2):627-35
pubmed: 24009950
Clin Chem. 2007 Jan;53(1):34-41
pubmed: 17040956
Cardiovasc Res. 2016 Aug 1;111(3):262-73
pubmed: 27229458
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Am J Cardiol. 2009 Oct 1;104(7):917-20
pubmed: 19766756
Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):136-42
pubmed: 16254208
Nat Rev Immunol. 2013 Jan;13(1):34-45
pubmed: 23222502
Eur Heart J. 2009 May;30(10):1229-36
pubmed: 19329498
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Cardiovasc Diabetol. 2017 Aug 8;16(1):98
pubmed: 28789657
N Engl J Med. 2008 Nov 20;359(21):2195-207
pubmed: 18997196
Anatol J Cardiol. 2015 Jun;15(6):450-5
pubmed: 25430410
Eur J Vasc Endovasc Surg. 2015 May;49(5):549-55
pubmed: 25800096
Scand J Clin Lab Invest. 2018 Oct;78(6):470-476
pubmed: 30261750
J Am Coll Cardiol. 2010 Oct 26;56(18):1506-12
pubmed: 20951328
Nature. 2011 May 19;473(7347):317-25
pubmed: 21593864
N Engl J Med. 2005 Apr 21;352(16):1685-95
pubmed: 15843671
J Am Soc Nephrol. 2007 Feb;18(2):407-13
pubmed: 17229907
Eur J Vasc Endovasc Surg. 2019 Jun;57(6):768-777
pubmed: 31164272